The efficacy and safety of combination therapy of adoptive immunotherapy with chemotherapy for advanced pancreatic cancer

The efficacy and safety of combination therapy of adoptive immunotherapy with chemotherapy for advanced pancreatic cancer - Combination therapy of immunotherapy with chemotherapy for pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011177

Enrollment

Registered

2013-07-11

Start date

2013-07-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable advanced pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pancreatic cancer diagnosed histologically 2. Age: more than 20 years old and 20 y 3. Patients treated with chemottherapy 4. Performance status: 0-2 5. Survival more than three months 6. Maintained bone marrow, liver function and renal function 7. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Interstitial pneumonia 2. Active autoimmune disease 3. Uncontroled infection 4. Severe drug allergy 5. Continued steroid therapy 6. Pregnancy 7. HIV or HTLV-1 positive

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	—

Secondary

Measure	Time frame
Survival rate (one year), Progression free survival, Quality of life (QOL), Tumor marker, Immunorogic reaction, The kind and frequency of side effect	—

Countries

Japan

Contacts

Public ContactYoshiaki Kawaguchi

Tokai University School of Medicine Gastroenterology

y711kawa@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results